Japanese generic drugs market set to grow 17.5% to 356B yen in 2010
The Japanese generic pharmaceuticals market will expand by 17.5% to 359.7 billion yen ($4.03 billion) in 2010 from 306.2 billion yen in 2007, due to government policies to promote the use of copy-cat medicines, including increasing the use of such drugs in hospitals through the introduction of the diagnosis procedure combination or a flat-sum reimbursement system, according to a recent survey conducted by Fuji Keizai, a Tokyo-based market research company.
Generics will account for 5.2% of total prescription medicine turnover in 2020, which will amount to 6,892.9 billion yen, compared with 4.7% of the 6,529.0-billion-yen market in 2007.
High-ratio areas
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze